This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by HERRÁN, A.
Right arrow Articles by VÁZQUEZ-BARQUERO, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HERRÁN, A.
Right arrow Articles by VÁZQUEZ-BARQUERO, J. L.
The British Journal of Psychiatry (2001) 179: 59-62
© 2001 The Royal College of Psychiatrists

Effects of long-term treatment with antipsychotics on serum leptin levels

ANDRÉS HERRÁN, MD

Clinical and Social Psychiatry Research Unit, Department of Psychiatry, University Hospital Marqués de Valdecilla, Santander, Spain

MARÍA TERESA GARCÍA-UNZUETA, MD and JOSÉ ANTONIO AMADO, MD

Department of Endocrinology, University Hospital Marqués de Valdecilla, Santander, Spain

MARÍA TERESA DE LA MAZA, MD and CONCEPCIÓN ÁLVAREZ, MD

Department of Biochemistry, University Hospital Marqués de Valdecilla, Santander, Spain

JOSÉ LUIS VÁZQUEZ-BARQUERO, FRCPsych

Clinical and Social Psychiatry Research Unit, Department of Psychiatry, University Hospital Marqués de Valdecilla, Santander, Spain

Correspondence: Andrés Herrán, Clinical and Social Psychiatry Research Unit, Department of Psychiatry, University Hospital Marqués de Valdecilla, Avda. de Valdecilla s/n, 39008 Santander, Spain. Tel: 34 942 202545; Fax: 34 942 203447; e-mail: herran{at}humv.es

Declaration of interest This study was supported by a grant from the Fundación Marqués de Valdecilla, 1996.

Background Abnormal regulation of the adipocyte-derived hormone leptin could play a role in body weight gain induced by antipsychotics.

Aims To study the effects of long-term antipsychotic treatment on leptin levels in patients with schizophrenia.

Method Serum leptin levels were determined in 59 out-patients with chronic schizophrenia and in the same number of healthy subjects controlled by gender, age and body mass index.

Results Leptin levels did not differ between patients and controls. Leptin levels in patients with schizophrenia correlated with weight gain, even after controlling for current weight, but did not show any association with clinical variables. Antipsychotic class tended to exert different effects over leptin levels (among atypicals, olanzapine induced a greater increase).

Conclusions Elevation of leptin levels induced by chronic antipsychotic treatment can be attributed to weight gain, but other mechanisms could be involved.




This article has been cited by other articles:


Home page
 Schizophr BullHome page
O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Schizophr Bull, November 1, 2008; 34(6): 1189 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol
Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment
J Psychopharmacol, November 1, 2007; 21(8): 857 - 863.
[Abstract] [PDF]

Home page
 Research on Social Work PracticeHome page
J. R. Bola
Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders
Research on Social Work Practice, May 1, 2006; 16(3): 263 - 275.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
J Psychopharmacol, January 1, 2006; 20(1): 75 - 79.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
V. J. Fedorowicz and E. Fombonne
Metabolic side effects of atypical antipsychotics in children: a literature review
J Psychopharmacol, September 1, 2005; 19(5): 533 - 550.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
E K. Hester and M. R Thrower
Current Options in the Management of Olanzapine-Associated Weight Gain
Ann. Pharmacother., February 1, 2005; 39(2): 302 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry, January 1, 2005; 62(1): 19 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
Z.-J. ZHANG, Z.-J. YAO, W. LIU, Q. FANG, and G. P. REYNOLDS
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia
The British Journal of Psychiatry, January 1, 2004; 184(1): 58 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
F. M. Wurst, G. Bechtel, S. Forster, M. Wolfersdorf, P. Huber, A. Scholer, L. Pridzun, A. Alt, S. Seidl, J. Dierkes, et al.
LEPTIN LEVELS OF ALCOHOL ABSTAINERS AND DETOXIFICATION PATIENTS ARE NOT DIFFERENT
Alcohol Alcohol., July 1, 2003; 38(4): 364 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. E.J. Lean and F.-G. Pajonk
Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes
Diabetes Care, May 1, 2003; 26(5): 1597 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
T. Baptista and S. Beaulieu
Leptin and antipsychotic drugs
The British Journal of Psychiatry, December 1, 2001; 179(6): 560 - 561.
[Full Text]